A Council of the Chamber of Commerce for Greater Philadelphia
LinkedInTwitterYouTube

Regional Leaders Praise Greater Philadelphia’s Culture, Cuisine, and Quality of Life

Life sciences companies looking to locate in Greater Philadelphia consider many factors in their decision making, from accessibility and connectivity to opportunities to collaborate and achieve their company’s vision. Another factor is the quality of life available to their employees. The Chamber of Commerce for Greater Philadelphia is developing a series of testimonial videos with Greater Philadelphia’s leaders describing the region’s attributes.

Among the region’s leaders who have already shared their perspectives are Chellie Cameron, CEO, Philadelphia International Airport and Northeast Philadelphia Airport, Chief Aviation Representative, City of Philadelphia – Division of Aviation; Roland Kolbeck, Ph.D., chief scientific officer at Spirovant […]

April 26th, 2022|Cell and Gene Therapy, Life Sciences, Livability|0 Comments
Read More

Medaglio to Direct Chamber’s Businesses Attraction & Expansion Efforts

The Chamber of Commerce for Greater Philadelphia is pleased to announce James Medaglio as Director, Business Attraction & Expansion. In this role, Medaglio will identify, engage, and assist companies looking to locate or expand in the Greater Philadelphia region.

It’s an assignment that Medaglio understands well. He first joined the Chamber in 2018 as a research analyst, providing support to business attraction projects, and more recently, serving as the point of contact for the organization’s Health and Life Sciences Action Team (HLSAT). He is looking forward to drawing on that expertise in his new position.

Among his responsibilities will be hosting visiting […]

February 28th, 2022|Advanced Manufacturing, Cell and Gene Therapy, Financial Services, Life Sciences, Our News, Technology|0 Comments
Read More

Surge in Life Sciences Investment in Region Continues: 2021 Total Exceeded $12 Billion

The life sciences sector in Greater Philadelphia benefited from robust investment in 2021. The 11-county area of Southeastern Pennsylvania, northern Delaware and southern New Jersey combined saw more than $12 billion invested, according to biopharma database company DealForma. The $12 billion tally included more than $3 billion for cell and gene therapy. Investment deals ranged from Series A rounds through IPOs. Among the technologies funded were biologics, cell and gene therapy, small molecules, as well as medical device and digital health, including artificial intelligence.

Reflected in the DealForma data were eight IPOs with a combined value of more than $750 million. […]

January 25th, 2022|Cell and Gene Therapy, Innovation, Investments, Life Sciences, Real Estate, Regional News Roundup|0 Comments
Read More

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Castle Creek Biosciences, Inc. announces research collaboration with Mayo Clinic.

Article from PR Newswire

September 29th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|0 Comments
Read More

Philadelphia’s startup ecosystem climbs 15 spots into the top 30 worldwide, report says

Philadelphia’s startup scene is ranked amongst the best-performing in the world according to Startup Genome.

Article from Philadelphia Business Journal 

September 22nd, 2021|Advanced Manufacturing, Cell and Gene Therapy, Financial Services, Innovation, Investments, Life Sciences, Regional News Roundup, Technology|0 Comments
Read More

Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Penn Medicine is one of 30 sites chosen by the National Institute of Health to serve as an Impact of Genomic Variation on Function investigator.

Article from Penn Medicine

September 16th, 2021|Cell and Gene Therapy, Investments, Largest Employers, Life Sciences, Regional News Roundup|Comments Off on Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease
Read More

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Roche’s Genetech has signed a deal to partner with Adaptimmune on off-the-shelf T cell therapies.

Article from Endpoints News

September 10th, 2021|Cell and Gene Therapy, Investments, Regional News Roundup|Comments Off on Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs
Read More

Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology

Director of the University of Pennsylvania’s gene therapy program, Dr. James Wilson, has formed a company specializing in gene editing.

Article from Philadelphia Business Journal

September 9th, 2021|Cell and Gene Therapy, Innovation, Investments, Regional News Roundup|Comments Off on Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology
Read More

Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy

A new study from Penn Medicine demonstrates a naturally occurring RNA can activate the body’s own natural T cells to seek out cancer cells that may have escaped recognition by CAR T cells.

Article from Penn Medicine

September 2nd, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy
Read More
Go to Top